Tadalafil — The Long-Acting PDE5 Inhibitor Behind Cialis

Medication Overview

Cialis and Tadalafil — What Distinguishes This Drug From Others in Its Class

Tadalafil is the active ingredient in Cialis, an oral tablet developed by Eli Lilly and ICOS Corporation and approved by the FDA in November 2003 for the treatment of erectile dysfunction. It belongs to the same PDE5 inhibitor class as sildenafil (Viagra), but tadalafil's unusually long plasma half-life of 17 to 18 hours sets it apart from every other drug in the category. A single dose can sustain pharmacological activity for up to 36 hours, which is why it earned the popular nickname "the weekend pill." Tadalafil is also approved under the brand name Adcirca for pulmonary arterial hypertension.

Mechanism: PDE5 Inhibition and the 36-Hour Window

Like all PDE5 inhibitors, tadalafil works by blocking the enzyme phosphodiesterase type 5, which degrades cyclic GMP in the smooth muscle cells of the penile arteries. By keeping cGMP elevated, tadalafil prolongs arterial relaxation and facilitates blood flow into erectile tissue during sexual stimulation. The drug does not produce an erection without stimulation; it enables the body's natural response to function more reliably.

What distinguishes tadalafil pharmacokinetically is its extended half-life. While sildenafil is largely cleared from plasma within 6 to 8 hours, tadalafil remains above therapeutic concentrations for up to 36 hours. This means a man can take a single tablet on Friday evening and remain pharmacologically responsive through the weekend — a convenience that many men find more aligned with the unpredictability of real-life sexual activity than a precisely timed shorter-acting drug.

Unlike sildenafil, tadalafil is not significantly affected by food. A high-fat meal does not meaningfully alter tadalafil's absorption or peak plasma concentration, giving users more flexibility about when they eat relative to when they take the medication.

FDA-Approved Indications

Tadalafil has three distinct regulatory approvals in the United States, each reflecting a specific clinical application:

  • Erectile dysfunction: approved for on-demand use (10 mg or 20 mg taken before sexual activity) and for once-daily use at lower doses (2.5 mg or 5 mg). Clinical trials show that tadalafil achieves satisfactory erections in approximately 67–75% of men across the ED indication, a figure comparable to sildenafil.
  • Benign prostatic hyperplasia (BPH): tadalafil 5 mg once daily is FDA approved for the urinary symptoms of BPH — the hesitancy, urgency, weak stream, and incomplete emptying caused by an enlarged prostate. The mechanism is independent of PDE5 inhibition for erections; tadalafil also relaxes smooth muscle in the bladder neck and prostate. This makes it a uniquely practical single-pill option for men managing both BPH and ED simultaneously.
  • Pulmonary arterial hypertension: at a dose of 40 mg once daily for PAH (marketed as Adcirca), tadalafil reduces pulmonary vascular resistance and improves exercise capacity. The 2009 PHIRST clinical trial demonstrated statistically significant improvement in six-minute walk distance in PAH patients treated with tadalafil compared to placebo.

How Tadalafil Compares to Other PDE5 Inhibitors

The most meaningful practical comparison is between tadalafil and sildenafil. Both block PDE5, both require sexual stimulation to produce an erection, and both carry the same absolute contraindication against concurrent nitrate use. The differences lie primarily in duration, food interactions, side effect profile, and approved indications:

  • Sildenafil lasts 4–6 hours; tadalafil lasts up to 36 hours.
  • Sildenafil is affected by high-fat meals; tadalafil is not.
  • Tadalafil is more likely to cause back pain and muscle aches (due to PDE11 inhibition in skeletal muscle); sildenafil is more likely to cause visual disturbances (due to mild PDE6 inhibition in the retina).
  • Tadalafil is the only PDE5 inhibitor with an FDA-approved indication for benign prostatic hyperplasia.

Questions Patients Commonly Ask Physicians

A frequently asked question is whether the 36-hour window means a man will have a prolonged erection for that entire time — the answer is no. Tadalafil remains in the bloodstream at pharmacologically relevant levels for up to 36 hours, but an erection still requires sexual stimulation and will subside naturally after activity ends. The drug does not cause persistent or involuntary erections except in the rare adverse event of priapism, which requires urgent medical attention.

Safety Profile

Side Effects Specific to Tadalafil

Tadalafil shares several side effects with other PDE5 inhibitors but has a distinctive profile at the margins:

  • Headache — the most common, reported in approximately 11% of ED patients in registration trials
  • Facial flushing and nasal congestion — similar in mechanism and frequency to sildenafil
  • Back pain and myalgia — characteristic of tadalafil specifically; attributed to inhibitory activity at PDE11 receptors in muscle tissue; typically appears 12 to 24 hours after dosing and resolves within 48 hours without treatment
  • Indigestion and dyspepsia — more common with tadalafil than with sildenafil according to comparative trial data

Visual disturbances — the blue-tinted vision associated with sildenafil's PDE6 activity — are rarely reported with tadalafil.

Contraindications and Blood Pressure Considerations

The most important contraindication for tadalafil is identical to that of all PDE5 inhibitors: concurrent use with any form of organic nitrate medication. Nitrates lower blood pressure through a cGMP-dependent pathway; tadalafil also raises cGMP levels. The combined effect can cause a sudden, severe, and potentially life-threatening fall in blood pressure.

Men with heart problems that are unstable, those who have had a recent heart attack or stroke, or those advised by their cardiologist to avoid sexual exertion are not candidates for tadalafil without specialist clearance. Men with significantly low resting blood pressure (below 90/50 mmHg) or uncontrolled high blood pressure should also discuss tadalafil risks with their physician before use.

Alpha-blockers (used for BPH and hypertension) interact with tadalafil and can cause symptomatic hypotension, particularly if both drugs are taken at the same time of day. Prescribers typically advise spacing them several hours apart and starting tadalafil at the lowest effective dose.

Tadalafil for Daily Low-Dose Use

The once-daily 2.5 mg and 5 mg regimens represent a fundamentally different approach to ED management compared to on-demand dosing. By maintaining a steady low level of PDE5 inhibition around the clock, the daily regimen eliminates the need to time a tablet before sexual activity. Some men report that this feels more natural and reduces performance-related anticipatory anxiety associated with taking a tablet in the moments before sex. Men on the daily regimen who have both ED and BPH can address both conditions with a single daily tablet at the 5 mg dose.

About This Page

This article is for informational purposes only and does not constitute medical advice. Clinical data are drawn from FDA prescribing information for tadalafil, the PHIRST clinical trial publication, and peer-reviewed comparative pharmacology reviews. Reviewed by a medical writing team, April 2026.